Obesity-related hypertension

被引:0
|
作者
Adamczak, Marcin [1 ]
Gojowy, Damian [1 ]
Wiecek, Andrzej [1 ]
机构
[1] Slaskiego Uniwersytetu Med Katowicach, Katedra & Klin Nefrol Transplantol & Chorob Wewne, Ul Francuska 20-24, PL-40027 Katowice, Poland
来源
ARTERIAL HYPERTENSION | 2014年 / 18卷 / 04期
关键词
hypertension; obesity; obesity-related hypertension; antihypertensive treatment in obese patients;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
For nearly a century, it is known that hypertension and obesity often coexist. The pathogenetic mechanisms leading to hypertension in obese patients are complex. The most important are: sympathetic nervous system overactivation, increased sodium reabsorption in the renal tubules leading to hypervolemia, insulin resistance, stimulation of the renin-angiotensin-aldosterone system and disturbances of the adipokines secretion. The goal of antihypertensive therapy in obese subjects is to obtain blood pressure below 140/90 mm Hg. Basic methods of antihypertension treatment in obese patients is to reduce body fat mass by calorie restrictive diet and increased physical activity. Recommended for advanced obesity bariatric surgery may also exert an antihypertensive effect. In pharmacotherapy of hypertension in obese patients preferentially are angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists. In order to obtain the target of blood pressure in these patients usually it is necessary to use two or more antihypertensive drugs.
引用
收藏
页码:224 / 236
页数:13
相关论文
共 50 条
  • [41] Hyperleptinemia as a risk factor in obesity-related hypertension
    Alvarez-Aguilar, C
    Mondragón-Jiménez, LI
    Ramírez-Enríquez, J
    Gómez-García, A
    Paniagua-Sierra, R
    Amato, D
    MEDICINA CLINICA, 2004, 123 (20): : 766 - 769
  • [42] Highlights of mechanisms and treatment of obesity-related hypertension
    Elham Shams
    Vijayvardhan Kamalumpundi
    Joshua Peterson
    Ronaldo Altenburg Gismondi
    Wille Oigman
    Marcelo Lima de Gusmão Correia
    Journal of Human Hypertension, 2022, 36 : 785 - 793
  • [43] Pathophysiological role of leptin in obesity-related hypertension
    Aizawa-Abe, M
    Ogawa, Y
    Masuzaki, H
    Ebihara, K
    Satoh, N
    Iwai, H
    Matsuoka, N
    Hayashi, T
    Hosoda, K
    Inoue, G
    Yoshimasa, Y
    Nakao, K
    JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09): : 1243 - 1252
  • [44] Increased circulating endothelin-1 in obesity-related hypertension, but not in obesity or hypertension alone
    Lilyasan, Oktavia
    Kosasih, Adrianus
    Liasturti, Lies D.
    Librantoro
    Gunawan, I. R.
    Idham, Idris
    Raharjo, Sunu B.
    Harimurti, Ganesja M.
    CIRCULATION, 2007, 116 (16) : 341 - 341
  • [45] Optimal treatment of obesity-related hypertension - The Hypertension-Obesity-Sibutramine (HOS) Study
    Scholze, Juergen
    Grimm, Elmar
    Herrmann, Dana
    Unger, Thomas
    Kintscher, Ulrich
    CIRCULATION, 2007, 115 (15) : 1991 - 1998
  • [46] Sympathoinhibitory signals from the gut and obesity-related hypertension
    Daniela M. Sartor
    Clinical Autonomic Research, 2013, 23 : 33 - 39
  • [47] PATHOPHYSIOLOGY AND TREATMENT OF THE OBESITY-RELATED ARTERIAL-HYPERTENSION
    KOLANOWSKI, J
    ACTA CLINICA BELGICA, 1992, 47 : 18 - 25
  • [48] Obesity-related hypertension: Is there a role for selective leptin resistance?
    Correia, MLG
    Haynes, WG
    CURRENT HYPERTENSION REPORTS, 2004, 6 (03) : 230 - 235
  • [49] Obesity-related hypertension: Is there a role for selective leptin resistance?
    Marcelo L. G. Correia
    William G. Haynes
    Current Hypertension Reports, 2004, 6 : 230 - 235
  • [50] Sympathoinhibitory signals from the gut and obesity-related hypertension
    Sartor, Daniela M.
    CLINICAL AUTONOMIC RESEARCH, 2013, 23 (01) : 33 - 39